In a groundbreaking development for mental health treatment, the U.S. Food and Drug Administration (FDA) has approved Cobenfy for the treatment of schizophrenia, marking the first new medication for the disorder in almost three decades. Developed by Karuna Therapeutics, now a subsidiary of Bristol Myers Squibb, Cobenfy employs a novel mechanism that distinguishes it from existing treatments.
Traditionally, schizophrenia medications primarily target the dopamine neurotransmitter system. In contrast, Cobenfy activates the cholinergic system through muscarinic receptors, offering a new approach to managing the disorder. The origins of this innovative treatment date back to research by Eli Lilly, which initially explored the muscarinic system for Alzheimer’s disease. Scientists discovered that compounds activating this system could alleviate symptoms of schizophrenia but encountered challenges in selectively targeting brain receptors without affecting other bodily systems.
Andrew Miller, co-founder of Karuna, sought to refine this approach. His team screened 7,000 compounds and successfully combined xanomeline, a previously shelved compound, with an FDA-approved medication for overactive bladder to minimize side effects elsewhere in the body. “It’s a pretty out-of-the-box approach,” Miller stated, highlighting the unconventional nature of their drug development strategy.
Clinical studies have shown promising results for Cobenfy. In a trial published in The Lancet, participants experienced significant reductions in schizophrenia symptoms, such as hallucinations and social withdrawal, compared to a placebo. Bristol Myers Squibb acquired Karuna in 2023, driven by these encouraging findings. Adam Lenkowsky, chief commercialization officer at Bristol Myers Squibb, emphasized the importance of introducing a revolutionary treatment rather than another dopamine-based option.
Dr. Rishi Kakar, chief scientific officer at Segal Trials, noted that only about 40% of patients respond to traditional dopamine-based treatments, with many discontinuing due to severe side effects. In trials of Cobenfy, patients received escalating doses of the drug or a placebo over five weeks, with results indicating a notable reduction in overall symptoms.
Approved as a monotherapy, Cobenfy will require further studies to assess its effectiveness in combination with existing treatments. Kakar anticipates that many clinicians will consider Cobenfy as a first-line option due to its robust symptom reduction.
The FDA label for Cobenfy includes warnings about potential side effects such as nausea, urinary retention, and increased heart rate, though these are generally mild to moderate. Bristol Myers Squibb is also exploring the drug’s potential for treating Alzheimer’s-related psychosis and other conditions.
The wholesale cost for a month’s supply of Cobenfy is projected to be $1,850, but insurance coverage could reduce this expense for many patients. With an estimated 80% of individuals with schizophrenia in the U.S. covered by Medicare or Medicaid, accessibility may improve for those in need of this innovative treatment.
As neuropsychiatry moves towards new breakthroughs, Cobenfy represents a significant step forward in the fight against schizophrenia, with the potential to pave the way for additional therapies in the future.
